甘露聚糖肽治疗小儿中性粒细胞减少症的临床观察  

Clinical Observation of Mannatide in the Treatment of Children with Neutropenia Syndrome

作　　者：朱秀云[1] 王小军[1] 刘新[1] 

机构地区：[1]首都医科大学宣武医院儿科,北京市100053

出　　处：《中国病案》2017年第9期107-109,共3页Chinese Medical Record

摘　　要：目的观察甘露聚糖肽治疗病毒感染性中性粒细胞减少症患儿的临床疗效。方法 50例患儿分别接受了对照组常规抗病毒药物治疗和试验组常规抗病毒药物治疗加甘露聚糖肽治疗,各25例。治疗有效的判断标准为末梢血中性粒细胞计数较治疗前至少增加30%以上。结果末梢血中性粒细胞计数显示治疗前试验组与对照组无统计学差异,分别为0.95±0.16与0.95±0.15;但治疗后试验组明显较对照组为高,分别为1.27±0.25与1.15±0.16,且试验组和对照组均较治疗前有明显改善。治疗有效率:试验组和对照组分别为96%(24/25)和28%(7/25),具有统计学差异。结论与病毒感染性中性粒细胞减少症患儿的常规抗病毒治疗相比,甘露聚糖肽进一步提升了中性粒细胞计数和改善了治疗有效率。Objective To observe the clinical efficacy of Mannatide in the treatment of children with neutropenia syndrome. Methods Fifty children with neutropenia syndrome were enrolled into this study. 25 patients as control group received the Conventional antiviral treatment, and the remaining ones as experimental group were managed with the conventional antiviral treatment plus Mannatide, which was orally given 5 ml each time, 3 times per day for 7 days. The effective treatment was defined as an increase of neutrophilic granulocyte count of more than 30% compared with one before treatment. Results In the neutrophilic granulocyte count, there was no difference before treatment between 2 groups （0. 95 ± 0. 16 vs 0. 95± 0. 15） ; However, a significant difference was detected after treatment between 2 groups （1.27 ± 0. 25 vs 1.15 ± 0. 16）; and there was significant difference after and before treatment in experimental group and control group. The clinical effective rate was 96% （24/25） and 28% （7/25） respectively. Conclusions Compare with the conventional antiviral treatment of children with neutropenia syndrome, the mannatide may supply an additional effectiveness to elevate the neutrophilic granulocyte count and improvement of the clinical effective rate.

关 键 词：甘露聚糖肽 中性粒细胞减少症 病毒感染 儿童 

分 类 号：R725.5[医药卫生—儿科]